← Back to Search

1 for Glioblastoma

Phase 1
Waitlist Available
Research Sponsored by Adnexus, A Bristol-Myers Squibb R&D Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up rt phase treatment weeks 1-3, 5, 7-10, day 1. post rt phase cycles 1-3, day 1; then day 1 every 3 cycles thereafter; eos visit
Awards & highlights

Study Summary

Rationale: In light of the demonstrated activity of anti-angiogenesis agents in rGBM, it is reasonable to postulate that adding these agents to standard RT and chemotherapy in the up-front management of newly diagnosed GBM may improve the clinical benefit. This study will examine the safety and tolerability of adding CT-322 to the standard radiation therapy/temozolomide (RT/TMZ) backbone of treatment for newly diagnosed GBM

Eligible Conditions
  • Glioblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~rt phase treatment weeks 1-3, 5, 7-10, day 1. post rt phase cycles 1-3, day 1; then day 1 every 3 cycles thereafter; eos visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and rt phase treatment weeks 1-3, 5, 7-10, day 1. post rt phase cycles 1-3, day 1; then day 1 every 3 cycles thereafter; eos visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Establish the recommended Phase 2 dose for the QW schedule of CT-322 for use in this combination
Evaluate the safety and tolerability of CT-322 administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM
Secondary outcome measures
Brain
To describe the PK of TMZ and its active metabolite (MTIC) when TMZ is administered alone and when it is co-administered with CT-322 to a subset of approximately 12 subjects with newly diagnosed GBM
To describe the peak and trough concentrations of CT-322 when administered alone and when co-administered with TMZ
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pegdinetanib
Not yet FDA approved
Radiation Therapy
2017
Completed Phase 3
~7250
Temozolomide
FDA approved

Find a Location

Who is running the clinical trial?

Adnexus, A Bristol-Myers Squibb R&D CompanyLead Sponsor
2 Previous Clinical Trials
112 Total Patients Enrolled
1 Trials studying Glioblastoma
72 Patients Enrolled for Glioblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
2008. "CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00768911.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top